BioSpace News Archive

A human hand and a robot hand shake hands over a white circle on a green background

Collaboration

VantAI Links With Halda in Potential $1B+ Proteomics Pact

VantAI will use its machine learning capabilities to identify novel target-effector pairs that Halda can use in designing its bifunctional small-molecule drugs.

August 19, 2025

·

2 min read

·

Tristan Manalac

Contemporary art collage. Businessmen, employees walking into open door symbolizing new opportunities. Way to success. Concept of business, promotion, motivation, ambitions and ideas

Immuno-oncology

Genentech Walks Away From $2B Partnership With Adaptive Biotechnologies

Adaptive and Genentech first partnered in 2018 to advance T cell receptor-based therapies for cancer.

August 19, 2025

·

1 min read

·

Tristan Manalac

Time elapses in achieving the goal. Deadline. Get off schedule. Make it before the end of the term. Overdue work. Loss of relevance. Decrease in achievements, obsolescence of tasks.

Gene therapy

Regenxbio’s Hunter Syndrome Gene Therapy Hit With 3-Month PDUFA Delay

The FDA has postponed its decision date for Regenxbio’s Hunter syndrome gene therapy to review additional longer-term clinical data for the asset.

August 19, 2025

·

2 min read

·

Tristan Manalac

Dirty vote collage concept. Voting hand gesture, putting money on ballot box. Dishonest election campaign. black and white illustration Isolated on blue background

Regulatory

Conflicts of Interest in Vaccine Committees Have Been Plunging for Decades

A new study in JAMA contradicts a series of statements made by HHS Secretary Robert F. Kennedy Jr. that paint vaccine advisory committees at the CDC and FDA as hopelessly corrupt.

August 19, 2025

·

4 min read

·

Dan Samorodnitsky

Abstract creative art collage, market declines in the stock market. The concept of collapse or bankruptcy.

Weight loss

Viking Crashes as Obesity Pill Delivers Over 12% Weight Loss

Viking Therapeutics’ VK2735 achieves a 10.9% placebo-adjusted weight loss at 13 weeks, but a less than ideal safety profile marred the results.

August 19, 2025

·

2 min read

·

Tristan Manalac

Accumulated problems, contradictions. Dead end, we need to go back. You cannot continue further. Complete impossibility to continue. Rejection of an idea. Hard sanctions. Fatal error.

Rare diseases

FDA Rejects PTC Therapeutics’ Friedreich’s Ataxia Drug

The small molecule, vatiquinone, had already flunked a Phase III trial, but the company pushed ahead with an approval bid anyway.

August 19, 2025

·

1 min read

·

Dan Samorodnitsky

Hands in black and white dropping a collection of pills on a pink background

Manufacturing

Oral Wegovy’s Pending Approval Puts Spotlight on Viability of High-Dose Peptides

While the 10-fold increase in dose over injectable Wegovy has raised questions about the launch, Novo Nordisk has assured investors it has the manufacturing capacity to roll out oral semaglutide without restrictions on supply.

August 19, 2025

·

5 min read

·

Nick Paul Taylor

Press Releases

Curant Rare Announces Exclusive Pharmacy Partnership for IWILFIN™, the First and Only FDA-Approved Oral Maintenance Therapy Shown to Cut the Risk of High-Risk Neuroblastoma Relapse in Half

August 19, 2025

·

4 min read

Press Releases

Northwest Biotherapeutics Announces the Passing of Its Senior Vice President and General Counsel, Mr. Les Goldman